Horizon Therapeutics plc: Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA (inebilizumab-cdon)

-- Analysis in The Journal of Neurology, Neurosurgery and Psychiatry demonstrate the direct effect of UPLIZNA on levels of sNFL and sGFAP, two key biomarkers strongly associated with NMOSD attacks

Related Keywords

United States ,Ireland ,Germany ,Neuroimmunol Neuroinflamm ,Rachel Vann ,Orhan Aktas ,Kristina Patterson ,Tina Ventura ,Facebook ,Product Communications ,Exchange Commission ,Nasdaq ,Department Of Neurology ,Twitter ,Instagram ,Linkedin ,Expanded Disability Status Scale ,Medical Faculty ,Neuromyelitis Optica Spectrum Disorder ,Hepatitisb Virus ,Progressive Multifocal Leukoencephalopathy ,Full Prescribing Information ,United States Securities ,Accessed April ,Scler Relat ,Vice President ,Chief Investor Relations Officer ,Horizon ,Herapeutics ,Biomarker ,Analysis ,Publication ,Highlights ,Signals ,Disability ,Worsening ,Ssociated ,Ith ,Euromyelitis ,Voptica ,Spectrum ,Disorder ,Nmosd ,Attacks ,Illustrates ,Efficacy , ,